Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 6Breast 3Thoracic 2Gynecologic 2Head & Neck 1Genitourinary 1

Conditions

Breast Neoplasms 10Stomach Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Salivary Gland Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic HER2-positive Breast Cancer 1Hemangiosarcoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 28Trastuzumab 16Paclitaxel 14Docetaxel 12Cyclophosphamide 11Capecitabine 11Nivolumab 9fludarabine 7Carboplatin 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Cisplatin 6Specimen Handling 5Leucovorin 5Irinotecan 5Injections 5Gemcitabine 5Fluorouracil 5Bevacizumab 5atezolizumab 4aldesleukin 4Taxes 4Ipilimumab 4Fluorodeoxyglucose F18 4Drug Therapy 4Cetuximab 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4zanidatamab 3veliparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Stomach Neoplasms × zanidatamab × Breast × Clear all
NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

BeiGene

Phase 1/2 Completed
71 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Jazz Pharmaceuticals

Phase 1 Completed
279 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡